Incidence of Guillain-Barre Syndrome Is Not Associated with Influenza Vaccination in the Elderly
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hankil | - |
dc.contributor.author | Kang, Hye-Young | - |
dc.contributor.author | Jung, Sun-Young | - |
dc.contributor.author | Lee, Young-Mock | - |
dc.date.accessioned | 2022-01-20T01:45:55Z | - |
dc.date.available | 2022-01-20T01:45:55Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/53924 | - |
dc.description.abstract | We aimed to analyze the incidence of Guillain-Barre syndrome (GBS) and its association with influenza vaccination (IV) in the elderly population. This study included 2470 patients hospitalized with GBS (G61.0) between 2014 and 2016 based on the Korean National Health Insurance Service (NHIS) claims data. We reviewed every medical claim in the 42 days preceding GBS diagnosis looking for precedent causes of GBS. To assess the relationship between IV and the development of GBS, data from the NHIS and the National Vaccination Registry were combined and analyzed. Using a self-controlled case series (SCCS) approach, we calculated the incidence rate ratio by setting the risk period as 42 days following vaccination. The annual background incidence of GBS was estimated at 4.15 per 100,000 persons. More than half of the patients with newly developed GBS had a previous infection or surgery. The incidence of GBS within 42 days of IV was estimated at 0.32 per 100,000 vaccinated persons. SCCS analysis showed that the risk of GBS was not significantly higher. While GBS can potentially develop from various infections, no association was found between GBS and IV. These results will contribute to developing an evidence-based vaccine policy that includes a clear causality assessment of adverse events. | - |
dc.format.extent | 13 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Incidence of Guillain-Barre Syndrome Is Not Associated with Influenza Vaccination in the Elderly | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/vaccines8030431 | - |
dc.identifier.bibliographicCitation | VACCINES, v.8, no.3, pp 1 - 13 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000586661800001 | - |
dc.identifier.scopusid | 2-s2.0-85089114726 | - |
dc.citation.endPage | 13 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | VACCINES | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | Guillain-Barre | - |
dc.subject.keywordAuthor | syndrome | - |
dc.subject.keywordAuthor | influenza vaccine | - |
dc.subject.keywordAuthor | incidence | - |
dc.subject.keywordAuthor | self-controlled case series | - |
dc.subject.keywordPlus | CASE SERIES | - |
dc.subject.keywordPlus | IMMUNIZATION-PROGRAM | - |
dc.subject.keywordPlus | UNITED-STATES | - |
dc.subject.keywordPlus | VACCINES | - |
dc.subject.keywordPlus | CAMPYLOBACTER | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | INFECTIONS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.